Add SubjectMark | Hide Original Post | Show Chart | Poster Summary |Vasogen Inc (NYSE:MEW - TSE:VAS) Immune Modulation Therapies | Stock Discussion Forums Share This Board

Moderated By: Smacs -- (Not Moderated) -- Started: 2/17/2000 6:12:00 AM  Revision History Vasogen has been touted by analysts as one of the most promising Biotechs in Canada with 3 products currently in clinical trials and another two only months away. That will put them in a very promising position with 5 products in clinical trials at one time! With an unbelieveable roster on their Scientific Advisory Panel and extremely positive results so far in both cardiovascular and immuno products, the future looks great for Vasogen. vasogen.com  Corporate Profile (from their website) Vasogen Inc. is focused on the development and commercialization of immune modulation therapies to advance the treatment of cardiovascular, autoimmune and related inflammatory diseases. These therapies utilize components derived from a sample of a patient's own blood that has been modified by physicochemical biological modifiers. Research has shown that returning modified cellular and extracellular blood components by intra-muscular injection down-regulates self-destructive immune system activity, resulting in lower levels of inflammation, less tissue damage, and a reduction in disease. The Company has immune modulation therapies in development for the treatment of cardiovascular and autoimmune disease, and for the prevention or amelioration of ischemia/reperfusion injury. Vasogen is also developing a process to prevent Graft-versus-Host Disease, a life threatening complication of bone marrow transplantation. Delivered by a platform medical device technology, Vasogen's therapies are designed to target fundamental disease causing processes more effectively while causing fewer side effects than current therapies. In collaboration with leading university centers, the Company has an active research and development program for new products. The Company controls the development and manufacture of its technologies for use in research and development activities and continues to advance its product development program to support future commercial scale production. The Company's policy is to secure intellectual property protection on inventions, technology, and improvements that are important to the development of its business and with respect to the application of its immune modulation therapies to the treatment of a number of disease indications. The Company intends to commercialize its immune modulation therapies by partnering with established health care companies.

Reply	Message Preview	From	Recs	Date
26	There's a more active VSGN thread here: [graphic]Subject 12072	DewDiligence_on_SI	-	08/30/2005 02:31 PM
25	Looks like this blow up today	David Culver	-	08/30/2005 01:15 PM
24	Interesting article about using modified blood in New Scientist.http://www.newsc	Stephen O	-	11/27/2003 08:24 AM
23	Not sure but I believe around the summer or next fall. We have a bit of waiting	David Culver	-	11/24/2003 08:31 PM
22	Anybody know when phase 3 will be over	Keith Fauci	-	11/24/2003 06:05 PM
21	What are you doing here? vsv	Keith Fauci	-	09/17/2003 08:34 PM
20	Nice move today we are on our way to $10.00	David Culver	-	09/16/2003 08:38 PM
19	Vasogen Inc VAS Shar	Cal Gary	-	05/30/2002 02:12 PM
18	Vasogen raises $25-million through financing Vas	Cal Gary	-	05/28/2002 12:22 PM
17	Vasogen arranges $17-million bought-deal financing Vasogen Inc VAS Shares issu	Cal Gary	-	05/07/2002 11:15 AM
16	Vasogen indentifies best psoriasis treatment schedule Vas	Cal Gary	-	03/14/2002 10:08 AM